Transcriptome Analysis Shows That IFN-I Treatment and Concurrent SAV3 Infection Enriches MHC-I Antigen Processing and Presentation Pathways in Atlantic Salmon-Derived Macrophage/Dendritic Cells

Cheng Xu, Øystein Evensen and Hetron Mweemba Munang’andu *

Department of Basic Sciences and Aquatic Medicine, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, P.O. Box 369, NO-0102 Oslo, Norway; cheng.xu@nmbu.no (C.X.); oystein.evensen@nmbu.no (Ø.E.)
* Correspondence: hetron@nmbu.no
Received: 28 February 2019; Accepted: 17 May 2019; Published: 22 May 2019

Abstract: Type I interferons (IFNs) have been shown to play an important role in shaping adaptive immune responses in addition to their antiviral properties in immune cells. To gain insight into the impact of IFN-I-induced pathways involved in early adaptive immune responses, i.e., antigen-presenting pathways, in an Atlantic salmon-derived (Salmo salar L.) macrophage cell line (TO-cells), we used a comparative de novo transcriptome analysis where cells were treated with IFN-I or kept untreated and concurrently infected with salmonid alphavirus subtype 3 (SAV3). We found that concurrent treatment of TO-cells with IFN-I and SAV3 infection (SAV3/IFN+) significantly enriched the major histocompatibility complex class I (MHC-I) pathway unlike the non-IFN-I treated TO-cells (SAV3/IFN−) that had lower expression levels of MHC-I pathway-related genes. Genes such as the proteasomal activator (PA28) and β-2 microglobulin (β2M) were only differentially expressed in the SAV3/IFN+ cells and not in the SAV3/IFN− cells. MHC-I pathway genes like heat shock protein 90 (Hsp90), transporter of antigen associated proteins (TAPs) and tapasin had higher expression levels in the SAV3/IFN+ cells than in the SAV3/IFN− cells. There were no MHC-II pathway-related genes upregulated in SAV3/IFN+ treated cells, and cathepsin S linked to the degradation of endosomal antigens in the MHC-II pathway was downregulated in the SAV3/IFN− cells. Overall, our findings show that concurrent IFN-I treatment of TO-cells and SAV3 infection enriched gene expression linked to the MHC-I antigen presentation pathway. Data presented indicate a role of type I IFNs in strengthening antigen processing and presentation that may facilitate activation particularly of CD8+ T-cell responses following SAV3 infection, while SAV3 infection alone downplayed MHC-II pathways.

Keywords: antigen; dendritic cells; IFN-I; macrophages; MHC; SAV3; TO-cells

1. Introduction

Since their discovery more than 50 years ago [1], interferons (IFNs) have for a long time only been known for their antiviral properties. Recent advances show that type I IFNs play an important role in modulating adaptive immune responses by playing a pivotal role in the differentiation of circulating monocytes into mature dendritic cells (DCs) and macrophages [1–4]. They have also been shown to promote the activation of naive CD8 T-cells into cytotoxic T-lymphocytes (CTLs), the polarization of T-helper (Th) cells into Th1 responses, and cross-priming of CD8+ T-cells through the stimulation of DCs [4–9]. As pointed out by Gessani et al. [10], the regulatory effects of type I IFNs on T-cell responses stem from their activation of antigen processing in proteasomal compartments, transportation of processed peptides to the endoplasmic reticulum (ER), packaging of processed peptides on major histocompatibility complex (MHC) molecules, and finally, presentation of MHC-peptide complexes to
naive T-cells. To do these things, type I IFNs up- or downregulate several genes that include MHC-I and II molecules, transport antigen associated proteins (TAPs), tapasin, proteasomal activator protein 28 (PA28), heat shock proteins (Hsps), gamma IFN inducible lysosomal thiol (GILT), and several other genes involved in antigen presentation [11–16]. In vivo studies on IFN-deficient mice confirmed the crucial role played by endogenous type I IFN in regulating MHC-I peptide complex formation and Hsp70 expression in DCs [17] while Lattanzi et al. [12] have shown that IFNα increases the capacity of DCs to produce high levels of TAP1/2 and tapasin via the modulation of proteasomal activity. These studies show that IFNs regulate the functions of antigen-presenting cells (APCs), such as macrophages and DCs, leading to the activation of T-cell responses [9,10,18,19].

Hence, in the present study we wanted to determine the profile of genes linked to antigen processing and presentation expressed by the macrophage/dendritic-like TO-cells, which are derived from Atlantic salmon head kidney leukocytes, infected with salmonid alphavirus subtype 3 (SAV3) using a comparative de novo transcriptome analysis. Macrophages and dendritic-like cells have been shown to play an important role in antigen presentation in fish and are widely distributed both in lymphoid and mucosal organs in finfish. By comparing the repertoire of genes expressed in SAV3/IFN+ TO-cells with those expressed in SAV3/IFN− cells, we wanted to determine the role of IFN-I in regulating the expression of antigen processing and presentation genes concurrently with SAV3 infection in TO-cells.

2. Materials and Methods

2.1. Cell Culture, Virus Infection, and IFN-I Treatment

TO-cells derived from Atlantic salmon head kidney leukocytes characterized to possess macrophage/dendritic cell-like properties [20,21], were propagated at 20 °C in HMEM (Eagle’s minimal essential medium (MEM) with Hanks’ balanced salt solution (BSS)) supplemented with L-glutamine, MEM nonessential amino acids, gentamicin sulfate, and 10% Fetal bovine serum. When the cells were 80% confluent, one batch was inoculated with 1 MOI (multiplicity of infection) SAV3 (GenBank accession JQ799139) [22] in triplicates while another batch was treated with 500 ng/mL of Atlantic salmon type I IFN [22] and was concurrently infected with SAV3 in triplicates. Thereafter, the SAV3-infected cells with and without IFN-I treatment were incubated at 15 °C in HMEM maintenance media supplemented with 2% FBS. The mock cells (TOmock) were non-infected and only treated with maintenance medium. Cells were harvested after 48 hours and used for total RNA extraction for RNA-seq and qRT-PCR analysis.

2.2. Total RNA Isolation

Extraction of total RNA was carried out using the RNeasy Mini Kit with on-column DNase treatment according to the manufacturers’ instructions (Qiagen, Hilden, Germany). The quality and concentration of RNA was analyzed using the ND1000 nanodrop (NanoDrop Technologies, Wilmington, DE, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

2.3. Library Construction, Sequencing, and Data Analysis for RNA-Seq

Library construction was carried out by pooling together triplicate samples obtained from total RNA extracted from IFN-treated TO-cells concurrently infected by SAV3. Library construction was also carried out by pooling together a triplicate of total RNA from non-IFN-treated cells infected with SAV3 plus TImock cells (non-treated/non-infected) for RNA-seq. Treatment of total RNA with DNase I to degrade any possible DNA contamination, enrichment using oligo(dT) magnetic beads, fragmented into approximately 200 bp fragments, synthesis of first-strand cDNA using random hexamer primers followed by synthesis of the second strand together with end reparation coupled with 3’-end single nucleotide A (adenine) addition, ligation of sequence adaptors to the fragments, and fragment enrichment by PCR amplification were also carried out as previously described in our
studies [23]. Thereafter, a quality check (QC step) was carried out using the Agilent 2100 Bioanalyzer and ABI StepOnePlus Real-Time PCR System (Waltham, MA, USA) to qualify and quantify the sample library. Subsequently, library products were used for RNA sequencing using Illumina HiSeq™ 2000 (San Diego, CA, USA), BGI-Hong Kong (Hong Kong, China) and clean reads were obtained after the removal of adaptor sequences together with reads having >10% of unknown bases and reads with low-quality bases (base with quality value ≤ 5) >50% in a read.

2.4. De Novo Assembly, Functional Annotation, and Gene Ontology Classification

Once a library of clean reads was prepared, clean reads were then used for de novo transcriptome assembly using the Trinity software (http://trinityrnaseq.sourceforge.net/) [24]. Thereafter, the assembled unigenes were annotated into different functional classifications after searching in different protein databases using the BlastX (version 2.2.23) alignment. The four public protein databases used comprised (i) National Center for Biotechnology Information (NCBI) non-redundant (NR), (ii) Swiss-Prot, (iii) Kyoto Encyclopedia of Genes and Genomes (KEGG), and (iv) Cluster of Orthologous Groups (COG) at e-value < 0.00001. The direction of the identified unigenes was determined by using the consensus sequence obtained from the four databases [23]. In the case of conflicting results between different databases, the priority order (i) NR, (ii) Swiss-Prot, (iii) KEGG, and (iv) COG was used. BlastX data were used to extract the coding regions (CDS) from unigene sequences and translate them into peptide sequences. Unigenes not identified by BlastX were analyzed using ESTScan to predict their CDS and to decide their sequence direction, while unigenes with NR annotation were further analyzed with Blast2GO (http://www.blast2go.org/) to obtain their gene ontology (GO) annotations. The identified unigenes were classified according to GO functions using the Web Gene Ontology (WEGO) annotation software.

2.5. Identification of Differentially Expressed Genes

Mapped read counts for each gene generated from the functional annotation above were normalized for RNA length and total read counts in each lane using the reads per kilobase per million method (RPKM). As such, the RPKM method allowed for direct comparison of the number of transcripts between IFN-treated and non-treated groups, which created the basis for identifying the differentially expressed genes (DEGs). We set the cutoff limit at 95% confidence interval for all RPKM values for each gene and used a rigorous algorithm to generate DEGs by comparing RPKM-mapped reads from IFN-treated and non-treated cells infected with SAV3 versus TO mock cells. Only DEGs with a threshold of false discovery rate (FDR) < 0.001 and an absolute value log2 ratio > 1 were considered differentially expressed. Thereafter, all identified DEGs were mapped to GO annotations using the Blast2GO software (http://www.blast2go.org/) and were later assigned KEGG ortholog (KOs) identifiers for pathway analysis using the KEGG database (http://www.genome.ad.jp/kegg). All comparisons were for TO mock against TO infected with SAV3, with or without IFN-1 treatment, and the results are reported as SAV3/IFN+ or SAV3/IFN−.

2.6. Validation of RNA-Seq Data

In order to confirm the validity of our RNA-seq data, eight randomly selected DEGs shown to be up- or downregulated by RNA-seq were used for quantitative real-time PCR (qRT-PCR) analysis using the QuantiFast SYBR Green RT-PCR Kit (Qiagen) and the LightCycler 480 system (Roche, Basel, Switzerland). For each gene, the quantity of template, master mix final volume, reverse transcriptase, PCR initiation activation, and cycles used per reaction were carried out as previously described [23]. Primer sequences used for qRT-PCR are shown in Table 1. The specificity of each PCR product from each primer pair was confirmed by melting curve analysis and agarose gel analysis while the $2^{-\Delta\Delta Ct}$ method was used to quantify the fold increase in gene expression levels relative to the control group. All quantifications were normalized using the β-actin endogenous gene.
Table 1. Primer sequences for real time (RT) PCR.

| Primer Name | Sequence         |
|------------|-----------------|
| HSP90      | F: CCACCATGGGCTACATGATG  |
|            | R: CTTCAACCCTTGTCATTC  |
| TAP1       | F: ACGGACCTGAAGCCTTTAC  |
|            | R: TCACACACAAACTCACACAC  |
| TAP2       | F: GGGAAACAGAAGACACAGAAG  |
|            | R: ATGCCCCAACAAAGGGAG  |
| β2M        | F: TCGTTGACTTGTGCTCATACAGC  |
|            | R: CAGGGTATTTCTATCTCCAAAAGTGTC  |
| MHC1       | F: CTGCATTGAGTGGCTGAAGA  |
|            | R: GGTGATCTTGTCCGTCTTTC  |
| MHCII      | F: TCTCCAGTCTGCCCTTCACC  |
|            | R: GAAACACAGGAGAACCACAC  |
| CathepsinS | F: CGAAGGGAGGTCTGGGAGAGGAAT  |
|            | R: GCCCAGGCTAAGGTGTGCAATGC  |
| CathepsinB | F: TGTGAGACTGGATACACCTGCTAC  |
|            | R: GCTCCTCCACAGGCTCGTCCTTC  |
| β-actin    | F: CCAGTCTGCTCAGTGAGGCA  |
|            | R: GGTCTCAACACATGACTCGTCTGGA  |

3. Results

3.1. KEGG Pathway Analysis

Table 2 shows that there are 41 unigenes belonging to the antigen processing and presentation pathway differentially expressed in the SAV3-infected cells while 35 were differentially expressed in the SAV3/IFN+ group, accounting for 0.44% and 2.15% of the annotated DEGs for each group, respectively. Table 2 shows that the antigen processing and presentation pathway designated as K04612 by KEGG analysis was significantly enriched ($p = 3.2132 \times 10^{-9}$) for the type I IFN-treated cells (SAV3/IFN+) and not enriched ($p = 0.9999$) for the non-IFN-treated (SAV3/IFN−) indicating that concurrent IFN-I treatment and SAV3 infection significantly enriched the antigen processing and presentation pathways in these cells. As such, the proportion of upregulated unigenes in the SAV3/IFN+ cells (91.43%, $n = 35$) was higher than that in the SAV3/IFN− cells (41.46%, $n = 41$). As shown in Table 3 and Figure 1, there were more downregulated unigenes in the SAV3/IFN− cells than in the SAV3/IFN+ cells. In order to better understand which components of the antigen processing and presentation pathway were involved, we investigated the gene profiles of the MHC-I and -II pathways expressed in SAV3/IFN+ and SAV3/IFN− cells.

Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis of antigen presentation pathway genes expressed in the TO-vs.-SAV3 and TO-vs.-SAV3/IFN.

| Parameters                               | TO-vs.-SAV3 | TO-vs.-SAV3/IFN |
|------------------------------------------|-------------|-----------------|
| Antigen presentation pathway ID          | K04612      | K04612          |
| DEG with pathway annotation of antigen presentation | 41 (0.44%) | 35 (2.15%) |
| Total DEG with pathway annotations       | 9315        | 1629            |
| All genes with pathway annotation of antigen presentation | 145        | 145            |
| Q-value                                  | 1.0000e+00 | 1.2654e−07     |
| p-value                                  | 0.9999      | 3.2132e−09     |
| Number of upregulated unigenes           | 17          | 32              |
| Number of downregulated unigenes         | 24          | 3               |
| Percentage of upregulated unigenes       | 41.46%      | 91.43%          |
| Percentage of downregulated unigenes     | 58.44%      | 8.57%           |

Note: SAV3—salmonid alphavirus subtype 3; IFN—interferon; DEG—differentially expressed gene.
3.2. Major Histocompatibility Complex I Pathway

Genes differentially expressed in response to SAV3 infection with or without IFN-I treatment, belonging to the MHC-I pathways were broadly classified into two groups, the proteasome and endoplasmic reticulum expressed genes.

3.2.1. Proteasome Genes

Among the proteasomal degradation pathway-related genes, proteasomal activator 28 (PA28) proteins was upregulated in the SAV3/IFN+ and not in the SAV3/IFN−. Heat shock protein 70 (Hsp70) was downregulated in the SAV3/IFN− while Hsp90 was upregulated in both SAV3/IFN+ and SAV3/IFN− (Table 3). However, expression levels of Hsp90 were higher in the SAV3/IFN+ cells (Table 4). In addition, among the proteasomal degradation pathway-related genes, proteasomal activator 28 (PA28) proteins was upregulated in the SAV3/IFN+ and not in the SAV3/IFN−. Heat shock protein 70 (Hsp70) was downregulated in the SAV3/IFN− while Hsp90 was upregulated in both SAV3/IFN+ and SAV3/IFN− (Table 3). However, expression levels of Hsp90 were higher in the SAV3/IFN+ cells (Table 4). On the contrary, only two unigenes were classified as MHC-I in the SAV3/IFN− cells of which one was upregulated while the other was downregulated. Overall, Figure 1 and Table 3 show that the number of unigenes upregulated in the SAV3/IFN+ cells was higher than that in the SAV3/IFN− cells. Figure 1 and Table 3 also show that the number of downregulated unigenes was higher in the SAV3/IFN− than that in the SAV3/IFN+ cells. Moreover, Table 4 shows that the fold increase in expression levels was higher in the SAV3/IFN+ cells than in the SAV3/IFN− cells.

![Upregulation and Downregulation](image_url)

**Figure 1.** Shows the distribution of upregulated and downregulated unigenes differentially expressed in the TO-vs.-SAV3 and TO-vs.-SAV3/IFN cells involved in the antigen processing and presentation pathway.
Table 3. Summary of number of antigen processing and presentation unigenes expressed in TO-vs.-SAV3/IFN and TO-vs.-SAV3.

| Gene Name                                      | Abbrev. | KEGG   | Up/Down | TO-vs.-SAV3 (Unigenes) | TO-vs.-SAV3/IFN (Unigenes) |
|------------------------------------------------|---------|--------|---------|------------------------|----------------------------|
| Cathepsin L                                    | CTSL    | K01365 | Up      | 3                      | 3                          |
| Class II transactivator                        | CIITA   | K08606 | Up      | 3                      | 3                          |
| Transport associated protein 2                 | TAP2    | K05654 | Up      | 2                      | 4                          |
| Transport associated protein 1                 | TAP1    | K05653 | Up      | 2                      | 2                          |
| TAP binding protein (tapasin)                  | TAPBP   | K08058 | Up      | 2                      | 3                          |
| Heat shock protein 90                          | HSP90   | K04090 | Up      | 5                      | 5                          |
| Major histocompatibility complex I             | MHC-1   | K06751 | Up      | 1                      | 12                         |
| Lyosphosphatidic acid receptor 5               | LPAR5   | K08390 | Up      | 1                      | 1                          |
| Proteasome activator 28                        | PA28    | K06697 | Up      | 1                      | 1                          |
| Beta-2-microglobulin                           | β2M     | K08055 | Up      | 1                      |                            |
| Major histocompatibility complex, class I      | MHC-1   | K06751 | Down    | 1                      |                            |
| Cyclic AMP response element-binding protein 1  | CREB-1  | K05870 | Down    | 5                      |                            |
| Heat shock protein 70                          | HSP70   | K09489 | Down    | 7                      |                            |
| PAX-interacting protein 1                      | PAXIP1  | K14972 | Down    | 1                      |                            |
| Recyclin-1                                     | RCY1    | K15071 | Down    | 1                      |                            |
| Non-specific serine/threonine protein kinase    | STK     | K08282 | Down    | 1                      |                            |
| Calreticulin                                   | CALR    | K08057 | Down    | 2                      | 1                          |
| Nuclear factor Y                               | NFXY    | K08066 | Down    | 1                      |                            |
| Filaggrin                                      | FLG     | K10384 | Down    | 1                      |                            |
| Regulatory factor X-associated protein          | RFXAP   | K08063 | Down    | 1                      |                            |
| Calnexin                                       | CANX    | K08054 | Down    | 2                      |                            |
| Gamma IFN inducible lysosome thiol             | GILT    | K08059 | Down    | 1                      |                            |
| Protein disulfide isomerase family A, member 3 | PDIA3   | K08056 | Down    | 1                      |                            |
| Total unigenes expressed                       |         |        |         | 41                     | 35                         |
### Table 4. Comparison of fold increase in expression level of antigen processing and presentation genes expressed in the TO-vs.-SAV3/IFN and TO-vs.-SAV3.

| Gene Name                                  | Abbrev. | KEGG       | Unigene | GeneBank       | Up/Down | Log2 Ratio (PD/TO) | p-Value    | Log2 Ratio (PD/TO) | p-Value    |
|--------------------------------------------|---------|------------|---------|----------------|---------|--------------------|------------|--------------------|------------|
| Cathepsin L                                | CTSL    | K01365     | Unigene20896 | BT043962.1 | Up     | 11.54              | 2.84E−51   |                    |            |
| Class II transactivator                     | CIITA   | K08060     | CL7384.1 | NP_001186995.1 | Up     | 9.31               | 1.22E−17   | 9.87               | 9.83E−25   |
| Transport associated protein 2             | TAP2    | K05654     | CL7651.1 | Z90329.1       | Up     | 4.18               | 1.14E−14   | 1.38               | 6.21E−08   |
| Transport associated protein 1              | TAP1    | K05653     | Unigene6385 | AF153538.1 | Up     | 1.52               | 2.83E−12   | 2.34               | 0          |
| TAP binding protein (taspelin)             | TAPBP   | K08058     | CL1564.1 | NM_001124553.1 | Up     | 1.85               | 3.36E−11   | 2.01               | 8.00E−30   |
| Heat shock protein 90                      | HSP90   | K04090     | CL11346.1 | NM_001173702.1 | Up     | 1.72               | 1.62E−73   | 3.00               | 7.42E−18   |
| Lysophosphatidic acid receptor 5           | LPAR5   | K08390     | Unigene7594 | NP_001133983.1 | Up     | 1.50               | 4.47E−57   |                    |            |
| Proteasome activator 28                    | PA28    | K06697     | CL10.2  | AC080763.1     | Up     |                    |            |                    |            |
| Beta-2-microglobulin                       | β2M     | K08055     | Unigene753.1 | AF180485  | Up     | 1.12               | 3.41E−27   |                    |            |
| Major histocompatibility complex, class 1  | MHC-1   | K06751     | Unigene8180 | L63541.1 | Up     |                    |            |                    |            |
| Major histocompatibility complex, class 1  | MHC-1   | K06751     | Unigene23484 | BT072706.1 | Down | −1.11              | 3.25E−06   |                    |            |
| Cyclic AMP response element-binding protein 1 | CREB-1  | K05870     | CL3991.2 | EMC9054.1     | Down | −2.52              | 7.25E−06   |                    |            |
| Heat shock protein 70                      | HSP70   | K09489     | CL1805.2 | NP_0099881.1  | Down | −1.03              | 6.00E−80   |                    |            |
| Pax-acting protein 1                       | Paxip1  | K14972     | CL5737.1 | NM_001025462.1 | Down | −1.68              | 3.83E−07   |                    |            |
| Recyculin-1                                | RCY1    | K15071     | CL1550.1 | NM_001165325.1 | Down | −1.65              | 4.03E−39   |                    |            |
| Non-specific serine/threonine protein kinase | STK     | T08282     | Unigene4701 | XM_000479880.1 | Down | −1.64              | 2.57E−14   |                    |            |
| Calreticulin                               | CALR    | K08057     | CL1908.1 | XM_000468445.1 | Down | −1.91              | 5.93E−07   | −1.33              | 1.66E−05   |
| Nuclear factor Y                           | NFY     | K08066     | CL10158.1 | AC133690.1    | Down | −1.39              | 1.67E−15   |                    |            |
| Filaggrin                                  | FLG     | K10384     | CL9396.1 | XM_003437908.1 | Down | −1.38              | 8.33E−29   |                    |            |
| Regulatory factor X                        | RFX     | K08063     | Unigene16842 | XM_004319280.1 | Down | −1.17              | 5.47E−05   |                    |            |
| Calnexin                                   | CANX    | K08054     | CL609.2  | AAC18011.1    | Down | −1.16              | 4.79E−54   |                    |            |
| Cathepsin S                                | CTSS    | K01365     | Unigene2181 | NP_001134963.1 | Down | −1.03              | 1.85E−61   |                    |            |
| Interferon, gamma-inducible protein 30     | GILT    | K08059     | Unigene12622 | AC167714.1 | Down |                    | −1.10      | 6.76E−06          |            |
| Protein disulfide isomerase family A, member 3 | PDIA3   | K08056     | Unigene19161 | NP_998070.1 | Down |                    | −1.05      | 7.23E−07          |            |
3.3. Major Histocompatibility Complex II Pathway

In general, Figure 2A,B shows that there were fewer genes differentially expressed in response to SAV3 infection in TO-cells belonging to the MHC-II pathway for both SAV3/IFN+ and SAV3/IFN− cells, and, of those differentially regulated, the genes were broadly classified into the endosomal and endolysosomal compartments.

Figure 2. Cont.
Figure 2. Shows antigen processing and pathways for the TO-vs.-SAV3/IFN and TO-vs.-SAV3 generated by the KEGG pathway software analysis. (A) Network pathway for TO-vs.-SAV3. (B) Network pathway of TO-vs.-SAV3/IFN antigen processing and presentation in TO-cells. Red squares depict upregulated genes, while green squares depict downregulated genes in the pathway. Dots, triangles and squares show broken down antigens as cytosolic antigens in MHC-I and endocytosed antigens in MHC-II pathways. Solid lines show activation and dotted lines show alternative pathways. The mixed shading of red/green squares represents a mixed population of upregulated and downregulated genes. Note that there were more downregulated genes in the type I IFN-treated cells (TO-vs.-SAV3/IFN) (Figure 2A) than in the non-treated cells (TO-vs.-SAV3) (Figure 2B).

3.3.1. Endosomal Compartment Genes

In the endosomal compartment, only the gamma IFN inducible lysosomal thiol gene (GILT) was downregulated in SAV3/IFN+ while no endosomal gene was differentially expressed in SAV3/IFN− (Table 4 and Figure 2B).

3.3.2. Endolysosomal Compartment Genes

In the endolysosomal compartment, only three cathepsin (cat) genes were differentially expressed in SAV3/IFN−, which included catL (CTSL) and CatS (CTSS). Among these, CTSL was upregulated while CTSS was downregulated (Table 4). Both Table 4 and Figure 2B show that there were no endolysosomal compartment genes expressed in the SAV3/IFN+ cells. In summary, only the SAV3/IFN− had upregulated genes (catL) while the SAV3/IFN+ had no upregulated genes.

3.4. Other Genes

Other genes differentially expressed in response to SAV3 infection in TO-cells (SAV3/IFN−) linked to antigen processing and presentation included the regulatory factor X (RFX), cyclic AMP (adenosine
monophosphate) response element binding protein (CREB), PAX (Paired box)-interacting protein 1 (PAXIPI), recycin-1 (RCY-1), filaggrin (FLG), and nuclear factor Y (NFY) genes, all downregulated (Tables 3 and 4). Other genes downregulated in the SAV3/IFN+ cells included protein disulfide isomerase family A, member 3 (PDIAS3) (Tables 3 and 4).

3.5. Quantitative Real Time PCR

Figure 3 shows selected genes for qRT-PCR analysis of the antigen presentation pathway genes detected by RNA-seq. Hsp90, TAP1 and 2, MHC-I, and β2M were upregulated in SAV3/IFN+ and SAV3/IFN− with expression level higher in the SAV3/IFN+. Cathepsin B and cathepsin S were downregulated in the SAV3/IFN− and upregulated in the SAV3/IFN+, which conforms to observations from RNA-seq data. MHC-II was not differentially expressed in any groups. Overall, Figure 3 shows that genes that were up- or downregulated by RNA-seq were also up- or downregulated by qRT-PCR thereby confirming the validity of our RNA-seq data.

Figure 3. Shows a significant linear correlation ($r = 0.8027, p = 0.0052$) between RNA-seq log2 fold change and quantitative RT-PCR data for the randomly selected genes generated as the mean of the fold increase in gene expression relative to the TO control group after normalization with beta-actin.

4. Discussion

4.1. KEGG Pathway Analysis

Pathway-based analysis of transcriptome data has emerged to be the most effective approach used for identifying network pathways of genes that regulate immune responses in different host cells. Using a comparative pathway analysis, we have shown that concurrent addition of IFN-I with SAV3 infection in TO-cells significantly enriched the antigen processing and presentation pathway for SAV3/IFN+ compared to that for SAV3/IFN−. As a result there were more genes upregulated linked to the MHC-I pathway in the SAV3/IFN+ in contrast to SAV3/IFN−. Further comparative analyses of individual genes expressed in the IFN-I-treated cells compared to the non-IFN-treated cells showed that all genes linked to the MHC-I pathway upregulated in the SAV3/IFN+ were higher than the levels expressed in SAV3/IFN−. These findings show an increase in genes associated with antigen processing and presentation via the MHC-I pathway in SAV3-infected TO-cells treated with IFN prior to infection which is in line with observations made by Lattanzi et al. [12], who showed that IFNα regulates cytosolic antigen processing and presentation via the MHC-I pathway in mouse DCs. Overall, the approach used in this study shows that combining de novo transcriptome assembly with KEGG pathway analysis can be used to identify the network pathway of genes induced by different regulatory cytokines in fish cells with potential APC properties.
4.2. MHC-I Pathway Analysis

Intracellular antigen processing is largely dependent on the degradation of cytosolic antigens into peptides using proteolytic enzymes [25]. In mammals, two major proteins that degrade cytosolic antigens into peptides in the proteasome are PA28 and Hsp90 [26–30], which have also been characterized in fish [31–34]. Yamano et al. [35] have shown that these proteins carry out antigen degradation independent of each other and interestingly Hsp90 was enriched in SAV3/IFN− whereas both Hsp90 and PA28 were enriched in SAV3/IFN+ cells. Yamano et al. [35] also pointed out that apart from playing a major role in antigen degradation, Hsp90 serves as a post proteasomal peptide carrier that delivers the processed peptides to the TAPs to prevent degradation of the processed epitopes by cytosolic peptidases [36]. It is likely that the SAV3/IFN+ that had higher Hsp90 levels had a corresponding higher capacity of transporting its peptides into the ER than the SAV3/IFN−, which could account for the high TAP levels together with ER downstream genes detected in the SAV3/IFN+ compared to SAV3/IFN−.

Once viral antigens are degraded into peptides in the proteasome, the processed peptides are transported into the lumen of the ER by the TAP transporters. In the ER, the peptides are transferred from the TAP transporters onto MHC-I molecules. The MHC-I molecules that bind to processed peptides are made of two chains namely the polymorphic MHC-1α chain and non-polymorphic β2M chain, which assemble in the ER to form the MHC-1α/β2M peptidic trimers [37,38]. Peaper and Cresswell [37] pointed out that formation of stable MHC-1α/β2M peptide is largely dependent on tapasin, which is responsible for optimal loading of the peptides onto the MHC-1α/β2M molecules. Additionally, calnexin (CANX) promotes the early folding of MHC-I heavy chains, while calreticulin (CALR) and ERp57 are involved in peptide loading onto the MHC-I molecules [37].

In this study, only tapasin was upregulated in both treatment/infection groups while CALR, ERp57, and CANX were either downregulated or not differentially expressed. It is interesting to note that β2M was only expressed in the SAV3/IFN+ cells, suggesting that the IFN-I-treated cells had higher capacity to form MHC-1α/β2M peptide complexes. In addition, the high levels of MHC-I and tapasin expressed in the SAV3/IFN+ suggest that this group potentially had a higher capacity of forming stable MHC-1α/β2M peptide complexes than the SAV3/IFN−. These findings are in agreement with Landis et al. [39] who showed upregulation of β2M and tapasin in rainbow trout macrophages infected by viral hemorrhagic septicemia virus (VHSV) and Hansen and La Patra [40] who showed β2M and MHC-I upregulation in infectious hematopoietic necrosis virus (IHNV)-infected cells, which coincided with type I IFN upregulation. Jorgensen et al. [41,42] showed MHC-I and β2M upregulation, which corresponded with upregulated of IFN-I when MHC-II was downregulated in Atlantic salmon infected with infectious salmon anemia virus (ISAV). They observed that this phenomenon was more pronounced in the head kidney and not in other organs of infected fish. They also noted that CD8α was upregulated during the viremia stage when CD4 was not differentially expressed. In this study, we found that genes linked to CD8+ T-cell activation were upregulated, while genes linked to CD4+ T-cell activation were not differentially expressed in SAV3/IFN+. Overall, these findings suggest that IFN-I enhances SAV3 antigen processing and presentation via the MHC-I pathway.

4.3. MHC-II Pathway Analysis

Antigen processing in the endosome involves the degradation of the endocytosed antigens using proteases [43]. For MHC-II molecules to bind the processed peptides, they must gain access into the endosomal MHC-II compartments (MIIC). To do so, newly synthesized MHC-II molecules bind to the non-polymorphic protein called the invariant chain (Ii or CD74) to form Ii-MHC-II complexes. The Ii protein contains targeting motifs that direct the MHC-II molecules to the MIICs [44]. Once in the MIICs, MHC-II molecules bound to Ii cannot bind the processed antigenic peptides until they have been proteolytically degraded and dissociated from the Ii-MHC-II complexes [45,46]. Degradation of the Ii-MHC-II complex is carried out in a series of steps using different proteins such as Cathepsin B (CTSB) until the MHC-II molecule is left with a fragment of Ii called CLIP (class II Ii peptide), which is
later replaced with peptides from endosomal degraded antigens [46,47]. Studies on human APCs have shown that the removal of CLIP is facilitated by human leukocyte antigen DM (HLA-DM) [44,46,48], whose interaction with MHC-II also edits the peptides bound to MHC-II by ensuring that only peptides with higher affinity are selected for presentation to CD4 T-cells [49,50]. To date no similar peptide editing system to the human HLA-DM has been characterized in teleosts fish [51]. However, indications are that MHC-II antigen presentation mechanisms found in mammals also exist in fish given that most of the genes linked to the MHC-II pathway found in mammals, inclusive of Ii [52,53] and MHC-II [54–57], have also been characterized in fish.

In this study, neither MHC-II nor Ii were differentially expressed in SAV3/IFN+ or SAV3/IFN−. CTSB was upregulated, which played a significant role in endosomal antigen degradation in the SAV3/IFN−, and not in the SAV3/IFN+, where the underlying mechanisms are not known or easily explained. Given that TO-cells used in this study were harvested at 48 hours post infection, it remains unknown whether subsequent follow-up beyond 48 hours post infection would have led to upregulation of MHC-II and Ii genes linked to SAV3 presentation via the MHC-II pathway. There is need for follow-up studies with sequential sampling post infection with our without treatment to determine whether SAV3 infections (in the absence of IFN-I) can lead to upregulation of MHC-II and Ii genes in TO-cells. However, the general failure to upregulate genes linked to the MHC-II pathway in SAV3/IFN+ further consolidates our notion that IFN-I treatment of TO-cells polarized SAV3 antigen presentation via the MHC-I pathway.

5. Conclusions

In this study, we have shown that IFN-I polarizes the upregulation of genes linked to SAV3 antigen processing and presentation via the MHC-I pathway in TO-cells. In addition, we have also shown that by combining comparative transcriptome analysis with network pathway analyses, it is possible to identify the most relevant genes and network pathways regulated by different cytokines in virus-infected fish cells. However, it is important to point out that the analyses carried out here were based on genes generated by de novo assembly, they do not show the functional mechanisms of these genes. Hence, there is need for follow-up studies to demonstrate the exact mechanisms used by these genes to activate the MHC-I pathway following IFN-I treatment and SAV3 infection in TO-cells. Even so, data presented here could serve as a roadmap for elucidating underlying mechanisms mediated by IFN-I to facilitate adaptive immune responses in fish.

6. Data Access

The RNA-sequencing data used in this study have been deposited in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) database accession number GSE64095 (www.ncbi.nih.gov/geo Accession number GSE64095).

Author Contributions: C.X. carried out laboratory experiments, performed data analysis, and wrote the manuscript; H.M.M. carried out data analysis, interpreted data, and wrote the manuscript; and Ø.E. mobilized resources, interpreted data, and wrote the manuscript. All authors read and approved the manuscript before submission for publication.

Acknowledgments: Funded by the Research Council of Norway under the “The Atlantic salmon genome sequence as a tool for precision breeding” project number 226275, together with the “Targeted disease prophylaxis in European fish farming” project, grant agreement 311993.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Vilcek, J. Fifty years of interferon research: Aiming at a moving target. *Immunity* 2006, 25, 343–348. [CrossRef] [PubMed]
2. Belardelli, F.; Gresser, I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. *Immunol. Today* 1996, 17, 369–372. [CrossRef]
3. Belardelli, F.; Ferrantini, M. Cytokines as a link between innate and adaptive antitumor immunity. *Trends Immunol.* 2002, 23, 201–208. [CrossRef]

4. Proietti, E.; Bracci, L.; Puzelli, S.; Di Pucchio, T.; Sestili, P.; De Vincenzi, E.; Venditti, M.; Capone, I.; Seif, I.; De Maeyer, E.; et al. Type I IFN as a natural adjuvant for a protective immune response: Lessons from the influenza vaccine model. *J. Immunol.* 2002, 169, 375–383. [CrossRef]

5. Bracci, L.; Schumacher, R.; Provenzano, M.; Adamina, M.; Rosenthal, R.; Groepen, C.; Zajac, P.; Lezzi, G.; Proietti, E.; Belardelli, F.; Spagnoli, G.C. Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require toll-like receptor triggering. *J. Immunother.* 2008, 31, 466–474. [CrossRef]

6. Tough, D.F. Modulation of T-cell function by type I interferon. *Immunol. Cell Biol.* 2012, 90, 492–497. [CrossRef]

7. Hervas-Stubbs, S.; Perez-Gracia, J.L.; Rouzaut, A.; Sanmamed, M.F.; Le Bon, A.; Melero, I. Direct Effects of Type I Interferons on Cells of the Immune System. *Clin. Cancer Res.* 2011, 17, 2619–2627. [CrossRef] [PubMed]

8. Le Bon, A.; Etchart, N.; Rossmann, C.; Ashton, M.; Hou, S.; Gewert, D.; Borrow, P.; Tough, D.F. Cross-priming of CD8(+) T cells stimulated by virus-induced type I interferon. *Nat. Immunol.* 2003, 4, 1009–1015. [CrossRef]

9. Le Bon, A.; Thompson, C.; Kamphuis, E.; Durand, V.; Roisman, C.; Kalinke, U.; Tough, D.F. Cutting edge: Enhancement of antibody responses through direct stimulation of B and T cells by type IIFN. *J. Immunol.* 2006, 176, 2074–2078. [CrossRef] [PubMed]

10. Gessani, S.; Conti, L.; Del, C.M.; Belardelli, F. Type I interferons as regulators of human antigen presenting cell functions. *Toxins (Basel)* 6, 1696–1723. [CrossRef]

11. Lapenta, C.; Santini, S.M.; Spada, M.; Donati, S.; Urbani, F.; Accapezzato, D.; Franceschini, D.; Andreotti, M.; Barnaba, V.; Belardelli, F. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. *Eur. J. Immunol.* 2006, 36, 2046–2060. [CrossRef]

12. Lattanzi, L.; Rozaer, C.; Marescotti, D.; D’Agostino, G.; Santodonato, L.; Cellini, S.; Belardelli, F.; Gavioli, R.; Ferrantini, M. IFN-alpha boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. *Immunobiology* 2011, 216, 537–547. [CrossRef]

13. Mohly, M.; Viale-Castellano, A.; Nunes, J.A.; Isnardon, D.; Olive, D.; Gaugler, W. IFN-alpha skews monocyte differentiation into toll-like receptor 7-expressing dendritic cells with potent functional activities. *J. Immunol.* 2003, 171, 3385–3393. [CrossRef]

14. Parlati, S.; Romagnoli, G.; Spadaro, F.; Canini, I.; Sirabella, P.; Borghi, P.; Ramoni, C.; Files, I.; Biccoa, S.; Gabriele, L.; et al. LOX-1 as a natural IFN-alpha-mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. *Blood* 2010, 115, 1554–1563. [CrossRef]

15. Santini, S.M.; Lapenta, C.; Logozzi, M.; Parlati, S.; Spada, M.; Di Pucchio, T.; Belardelli, F. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. *J. Exp. Med.* 2000, 191, 1777–1788. [CrossRef]

16. Tosello, F.; Zamarchi, R.; Merlo, A.; Gorza, M.; Piovan, E.; Mandruzzato, S.; Bronte, V.; Wang, X.H.; Ferrone, S.; Amadori, A.; et al. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. *Eur. J. Immunol.* 2009, 39, 56–66. [CrossRef]

17. Spadaro, F.; Lapenta, C.; Donati, S.; Abalsamo, L.; Barnaba, V.; Belardelli, F.; Santini, S.M.; Ferrantini, M. IFN-alpha enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. *Blood* 2012, 119, 1407–1417. [CrossRef]

18. Ito, T.; Amakawa, R.; Inaba, M.; Ikehara, S.; Inaba, K.; Fukushima, S. Differential regulation of human blood dendritic cell subsets by IFNs. *J. Immunol.* 2001, 166, 2961–2969. [CrossRef]

19. Radvanyi, L.G.; Banerjee, A.; Weir, M.; Messner, H. Low levels of interferon-alpha induce CD86 (B7.2) expression and accelerates dendritic cell maturation from human peripheral blood mononuclear cells. *Scand. J. Immunol.* 1999, 50, 499–509. [CrossRef]

20. Pettersen, E.F.; Ingerslev, H.C.; Stavang, V.; Egenberg, M.; Wergeland, H.I. A highly phagocytic cell line TO from Atlantic salmon is CD83 positive and M-CSFR negative, indicating a dendritic-like cell type. *Fish Shellfish Immunol.* 2008, 25, 809–819. [CrossRef]

21. Wergeland, H.I.; Jakobsen, R.A. A salmonid cell line (TO) for production of infectious salmon anaemia virus (ISAV). *Dis. Aquat. Organ.* 2001, 44, 183–190. [CrossRef]
22. Xu, C.; Guo, T.C.; Mutoloki, S.; Haugland, O.; Marjara, I.S.; Evensen, O. Alpha Interferon and Not Gamma Interferon Inhibits Salmonid Alphavirus Subtype 3 Replication In Vitro. *J. Virol.* 2010, 84, 8903–8912. [CrossRef] [PubMed]

23. Xu, C.; Evensen, O.; Munang’andu, H.M. De novo assembly and transcriptome analysis of Atlantic salmon macrophage/dendritic-like TO cells following type I IFN treatment and Salmonid alphavirus subtype-3 infection. *BMC Genom.* 2015, 16, 96. [CrossRef] [PubMed]

24. Hua, W.P.; Zhang, Y.; Song, J.; Zhao, L.J.; Wang, Z.Z. De novo transcriptome sequencing in Salvia miltiorrhiza to identify genes involved in the biosynthesis of active ingredients. *Genomics* 2011, 98, 272–279.

25. Munang’andu, H.M.; Evensen, O. A Review of Intra- and Extracellular Antigen Delivery Systems for Virus Vaccines of Finfish. *J. Immunol. Res.* 2015, 2015. [CrossRef]

26. Rock, K.L.; Goldberg, A.L. Degradation of cell proteins and the generation of MHC class I-presented peptides. *Annu. Rev. Immunol.* 1999, 17, 739–779. [CrossRef]

27. Tanaka, K.; Chiba, T. The proteasome: A protein-destroying machine. *Genes Cells* 1998, 3, 499–510. [CrossRef] [PubMed]

28. Tanaka, K. Molecular biology of the proteasome. *Biochem. Biophys. Res. Commun.* 1998, 247, 537–541. [CrossRef]

29. Tanaka, K.; Kasahara, M. The MHC class I ligand-generating system: Roles of immunoproteasomes and the interferon-gamma-inducible proteasome activator PA28. *Immunol. Rev.* 1998, 163, 161–176. [CrossRef]

30. Yamano, T.; Mizukami, S.; Murata, S.; Chiba, T.; Tanaka, K.; Udono, H. Hsp90-mediated assembly of the 26 S proteasome is involved in major histocompatibility complex class I antigen processing. *J. Biol. Chem.* 2001, 276, 17163–17171. [CrossRef] [PubMed]

31. Kashturt, S.R.; Umasuthan, N.; Whang, I.; Kim, E.; Park, H.C.; Lee, J. Genomic structural characterization and transcriptional expression analysis of proteasome activator PA28 alpha and PA28 beta subunits from Oplegnathus fasciatus. *Fish Shellfish Immunol.* 2013, 35, 1224–1234. [CrossRef]

32. Kim, D.H.; Lee, S.M.; Hong, B.Y.; Kim, Y.T.; Choi, T.J. Cloning and sequence analysis of cDNA for the proteasome activator PA28-beta subunit of flounder (*Paralichthys olivaceus*). *Mol. Immunol.* 2003, 40, 611–616. [CrossRef]

33. Liu, G.Z.; Zheng, W.B.; Chen, X.H. Molecular cloning of proteasome activator PA28-beta subunit of large yellow croaker (*Pseudosciana crocea*) and its coordinated up-regulation with MHC class I alpha-chain and beta(2)-microglobulin in poly I:C-treated fish. *Mol. Immunol.* 2007, 44, 1190–1197. [CrossRef]

34. Pan, F.; Zarate, J.M.; Tremblay, G.C.; Bradley, T.M. Cloning and characterization of salmon hsp90 cDNA: Upregulation by thermal and hyperosmotic stress. *J. Exp. Zool.* 2000, 287, 199–212. [CrossRef]

35. Yamano, T.; Murata, S.; Shimbara, N.; Tanaka, N.; Chiba, T.; Tanaka, K.; Udono, H. Two distinct pathways mediated by PA28 and hsp90 in major histocompatibility complex class I antigen processing. *J. Exp. Med.* 2002, 196, 185–196. [CrossRef]

36. Binder, R.J.; Blachere, N.E.; Srivastava, P.K. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. *J. Biol. Chem.* 2001, 276, 17163–17171. [CrossRef]

37. Peaper, D.R.; Cresswell, P. Regulation of MHC Class I Assembly and Peptide Binding. *Annu. Rev. Cell Dev. Biol.* 2008, 24, 343–368. [CrossRef]

38. Mantegazza, A.R.; Magalhaes, J.G.; Amigorena, S.; Marks, M.S. Presentation of Phagocytosed Antigens by MHC Class I and II. *Traffic* 2013, 14, 135–152. [CrossRef]

39. Landis, E.D.; Palti, Y.; Dekoning, J.; Drew, R.; Phillips, R.B.; Hansen, J.D. Identification and regulatory analysis of rainbow trout tapasin and tapasin-related genes. *Immunogenetics* 2006, 58, 56–69. [CrossRef]

40. Hansen, J.D.; La Patra, S. Induction of the rainbow trout MHC class I pathway during acute IHNV infection. *Immunogenetics* 2002, 54, 654–661. [CrossRef]

41. Jorgensen, S.M.; Lyng-Syvertsen, B.; Lukacs, M.; Grimholt, U.; Gjøen, T. Expression of MHC class I pathway genes in response to infectious salmon anaemia virus in Atlantic salmon (*Salmo salar* L.) cells. *Fish Shellfish Immunol.* 2006, 21, 548–560. [CrossRef]

42. Jorgensen, S.M.; Hetland, D.L.; Press, C.M.; Grimholt, U.; Gjøen, T. Effect of early infectious salmon anaemia virus (ISAV) infection on expression of MHC pathway genes and type I and II interferon in Atlantic salmon (*Salmo salar* L.) tissues. *Fish Shellfish Immunol.* 2007, 23, 576–588. [CrossRef]
43. Deussing, J.; Roth, W.; Saftig, P.; Peters, C.; Ploegh, H.L.; Villadangos, J.A. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. *Proc. Natl. Acad. Sci. USA* 1998, 95, 4516–4521. [CrossRef]

44. Roche, P.A.; Furuta, K. The ins and outs of MHC class II-mediated antigen processing and presentation. *Nat. Rev. Immunol.* 2015, 15, 203–216. [CrossRef]

45. Cresswell, P.; Androlewicz, M.J.; Ortmann, B. Assembly and Transport of Class-I Mhc-Peptide Complexes. *Vaccines Against Virally Induced Cancers* 1994, 187, 150–169.

46. Cresswell, P. Assembly, Transport, and Function of Mhc Class-Ii Molecules. *Annu. Rev. Immunol.* 1994, 12, 259–293. [CrossRef]

47. Avva, R.R.; Cresswell, P. Alpha-Beta-Clip—An Intermediate in Mhc Class-Ii Processing. *J. Cell. Biochem.* 1994, 58, 330.

48. Avva, R.R.; Cresswell, P. In-Vivo and In-Vitro Formation and Dissociation of Hla-Dr Complexes with Invariant Chain-Derived Peptides. *Immunity* 1994, 1, 763–774. [CrossRef]

49. Katz, J.F.; Stebbins, C.; Appella, E.; Sant, A.J. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules. *J. Exp. Med.* 1996, 184, 1747–1753. [CrossRef]

50. Kropshofer, H.; Hammerling, G.J.; Vogt, A.B. How HLA-DM edits the MHC class II peptide repertoire: Survival of the fittest? *Immunol. Today* 1997, 18, 77–82. [CrossRef]

51. Dijkstra, J.M.; Grimholt, U.; Leong, J.; Koep, B.F.; Hashimoto, K. Comprehensive analysis of MHC class II genes in teleost fish genomes reveals dispensability of the peptide-loading DM system in a large part of vertebrates. *BMC Evol. Biol.* 2013, 13, 260. [CrossRef] [PubMed]

52. Dijkstra, J.M.; Kiryu, I.; Kollner, B.; Yoshiura, Y.; Ototake, M. MHC class II invariant chain homologues in rainbow trout (*Oncorhynchus mykiss*). *Fish Shellfish Immunol.* 2003, 15, 91–105. [CrossRef]

53. Yoder, J.A.; Haire, R.N.; Litman, G.W. Cloning of two zebrafish cDNAs that share domains with the MHC class II-associated invariant chain. *Immunogenetics* 1999, 50, 84–88. [PubMed]

54. Hetland, D.L.; Jorgensen, S.M.; Skjodt, K.; Dale, O.B.; Falk, K.; Xu, C.; Mikalsen, A.B.; Grimholt, U.; Gjøen, T.; Press, C.M. In situ localisation of major histocompatibility complex class I and class II and CD8 positive cells in infectious salmon anaemia virus (ISAV)-infected Atlantic salmon. *Fish Shellfish Immunol.* 2010, 28, 30–39. [CrossRef] [PubMed]

55. Li, H.J.; Jiang, L.X.; Han, J.B.; Su, H.; Yang, Q.; He, C.B. Major histocompatibility complex class IIA and IIB genes of the spotted halibut Verasper variegatus: Genomic structure, molecular polymorphism, and expression analysis. *Fish Physiol. Biochem.* 2011, 37, 767–780. [CrossRef]

56. Star, B.; Nederbragt, A.J.; Jentoft, S.; Grimholt, U.; Malmstrom, M.; Gregers, T.F.; Rouge, T.B.; Paulsen, J.; Solbakken, M.H.; Sharma, A.; et al. The genome sequence of Atlantic cod reveals a unique immune system. *Nature* 2011, 477, 207–210. [CrossRef] [PubMed]

57. Star, B.; Jentoft, S. Why does the immune system of Atlantic cod lack MHC II? *Bioessays* 2012, 34, 648–651. [CrossRef]